Proving Utility of a New Field-cycling MRI Prototype in Acute Stroke Patients

NCT ID: NCT07004140

Last Updated: 2026-01-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

40 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-09-16

Study Completion Date

2026-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this study is to test if a new type of MRI scanner, called Field-Cycling Imaging (FCI), can show changes in the brain within the first day of a stroke due to a blocked blood vessel or bleeding in the brain. The main question it aims to answer is:

• Can FCI identify brain tissue that might recover within the first few hours after a stroke begins?

Participants will undergo a standard MRI scan and an FCI scan, as soon as possible after hospital admission.

Participants who have had a blocked blood vessel will also provide a blood sample and will have a follow up visit at 30 days for repeat of both scans and providing another blood sample.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stroke Acute

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ischaemic stroke

Ischaemic stroke patients within 24 hours from symptom onset

3T MRI research scan

Intervention Type OTHER

Baseline MRI scan

Field-Cycling Imaging research scan

Intervention Type OTHER

Baseline FCI scan

Follow up 3T MRI research scan

Intervention Type OTHER

Day 30 3T MRI scan

Follow up Field-Cycling Imaging research scan

Intervention Type OTHER

Day 30 FCI scan

Blood samples for clotting experiments in vitro

Intervention Type OTHER

Thrombi from whole blood from ischaemic stroke patients will be formed and examined using bench top nuclear magnetic resonance (NMR) assays. At baseline and 30 days after stroke onset.

Haemorrhagic stroke

Patients with primary intracerebral haemorrhage within 24 hours from symptom onset

3T MRI research scan

Intervention Type OTHER

Baseline MRI scan

Field-Cycling Imaging research scan

Intervention Type OTHER

Baseline FCI scan

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

3T MRI research scan

Baseline MRI scan

Intervention Type OTHER

Field-Cycling Imaging research scan

Baseline FCI scan

Intervention Type OTHER

Follow up 3T MRI research scan

Day 30 3T MRI scan

Intervention Type OTHER

Follow up Field-Cycling Imaging research scan

Day 30 FCI scan

Intervention Type OTHER

Blood samples for clotting experiments in vitro

Thrombi from whole blood from ischaemic stroke patients will be formed and examined using bench top nuclear magnetic resonance (NMR) assays. At baseline and 30 days after stroke onset.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Acute stroke (\<24 hours from symptom onset).
* NIHSS ≥4 and \<25 with cortical involvement and/or large vessel occlusion on baseline imaging.
* Able to undergo 3T and FCI MRI \<24h of onset.
* With or without thrombolysis.

Exclusion Criteria

* Contraindications to MRI.
* Medically unstable.
* Unable to comprehend or comply with instructions regarding scanning
* Prior mRS of \>3.
* Identified for thrombectomy.
* Non-stroke pathology or previous cortical infarct on CT scan \> 1/3 of middle cerebral artery territory.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

NHS Grampian

OTHER_GOV

Sponsor Role collaborator

University of Aberdeen

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Aberdeen

Aberdeen, , United Kingdom

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Mary Joan MacLeod, PhD

Role: CONTACT

+44 1224 437842

Gordon D Waiter, PhD

Role: CONTACT

+44 1224 438356

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Mary Joan MacLeod, PhD

Role: primary

+44 1224 437842

Gordon D Waiter, PhD

Role: backup

+44 1224 438356

References

Explore related publications, articles, or registry entries linked to this study.

Mallikourti V, Ross PJ, Maier O, Guzman-Gutierrez G, Franko E, Lurie DJ, Broche LM, Macleod MJ. Field-Cycling MRI for Identifying Minor Ischemic Stroke Below 0.2 T. Radiology. 2024 Aug;312(2):e232972. doi: 10.1148/radiol.232972.

Reference Type BACKGROUND
PMID: 39189899 (View on PubMed)

Senn N, Ross PJ, Ayde R, Mallikourti V, Krishna A, James C, de Vries CF, Broche LM, Waiter GD, MacLeod MJ. Field-cycling imaging yields repeatable brain R1 dispersion measurement at fields strengths below 0.2 Tesla with optimal fitting routine. MAGMA. 2025 Jul;38(3):465-474. doi: 10.1007/s10334-025-01230-w. Epub 2025 Feb 15.

Reference Type BACKGROUND
PMID: 39955477 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

25/SS/0021

Identifier Type: OTHER

Identifier Source: secondary_id

2-001-25

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.